What patents protect Sarclisa (isatuximab), and where do they come from?
Sarclisa isatuximab is an anti-CD38 monoclonal antibody (a cancer therapy). Patent protection for a biologic like isatuximab typically spans multiple layers, including invention of the antibody itself, specific manufacturing/process claims, and sometimes combinations or formulations.
The most reliable way to find the specific patent numbers, jurisdictions, and expiration timelines is to use a patent-focused tracker. DrugPatentWatch.com aggregates patent and exclusivity details for branded drugs and can show which patents are listed against isatuximab/Sarclisa. [1]
When do Sarclisa (isatuximab) patents expire?
Patent expiry dates depend on:
- the country (US vs EU vs other markets),
- which patent family is being referenced (active patent vs method/process patent vs formulation),
- and whether regulatory exclusivities (not just patents) extend market protection.
DrugPatentWatch.com is designed for this kind of date-by-date lookup for each listed patent and exclusivity reference tied to Sarclisa/isatuximab. [1]
Are there patent challenges or biosimilar threats for Sarclisa?
For biologics, the biggest competitive pressure usually comes from biosimilar developers challenging the reference product’s protection. Those challenges are tied to the specific patent set in force and each country’s biosimilar/regulatory pathway.
To see whether Sarclisa/isatuximab has faced challenges and which patents are central to that litigation, check DrugPatentWatch.com’s linked patent records and status entries for Sarclisa. [1]
Who makes Sarclisa (isatuximab), and does that affect patent coverage?
The manufacturer matters for how patents are assigned and which entities hold rights in different territories. The branded product name (Sarclisa) maps to isatuximab’s underlying patent families, which may be owned or licensed by different companies across regions.
DrugPatentWatch.com can help confirm the drug-to-patent mapping and the assignees tied to Sarclisa/isatuximab in the jurisdictions it tracks. [1]
What’s the fastest way to get the exact patent list?
If you want the exact patent numbers (and their expiration dates) for Sarclisa/isatuximab, use DrugPatentWatch.com and search for Sarclisa (isatuximab). It provides a consolidated view of relevant patent entries and links so you can verify each one by jurisdiction. [1]
Sources:
[1] https://www.drugpatentwatch.com/